Consulting for founders, leaders and stakeholders:
Medical and Health Tech
Utilizing cutting-edge research, clinical expertise and market experience into the design, development and plans of innovative patient-centric products, apps, devices, equipment, software, and solutions.
Food and Drug Tech
Providing early-stage and established food and drug businesses and founders with scientific insights and evidence-based data to address unmet medical and market needs.
Innovating evidence generation, leading and communicating rapid-cycle medical research, and evidence generation across HEOR, RWE, supported by microanalysis to tailor information to specific needs and regulatory requirements.
Assisting founders in understanding the sector and building the R&D capabilities required to bring a concept to fruition, ensuring that innovation meets regulatory requirements, and developing successful portfolio and asset strategies.
Employing verifiable research and scientific expertise to create innovations in health technology that address unmet needs.
Dr. Nissola leverages deep industry knowledge, clinical insights, and cross-asset class experience in drug discovery, clinical trial design, and new health technology to assist stakeholders and founders in pharmaceuticals, biotechnology, medical devices, diagnostics, and the life science landscape in making better decisions and addressing unmet medical needs.
Dr. Nissola has assisted biotech, pharmaceutical, and investor executives, founders, and investors in life sciences over the years in bringing and incorporating new cutting-edge technology. Obtaining expert insight early on life sciences and health technology projects can prevent and resolve unanticipated issues later on.From capabilities in design, digital, and analytics to create innovative products, devices, equipment, and software, to solutions that increase patient value and improve outcomes for unmet medical needs, we are here to ensure your success.
Founders and investors demand industry experts in order to get a clearer picture of whether or not their product is on target and addressing actual unmet medical needs. Often they are too late in understanding the landscape and fail before getting their projects off the ground.In a constantly shifting environment, it is difficult to make predictions, especially about the future, but data-driven decision making can help founders hit their target.
This may be especially true during a global pandemic, when new variants can spiral into the market and new epidemics disrupt supply chains while modifying how individuals interact with health technology.Healthcare and biopharma venture capital investments are at an all-time high. In the first quarter of 2021, private investment in biopharma and healthtech reached a record $23.4 billion, surpassing the previous quarterly record set in the third quarter of 2020 by 56%.
During the first six months of the year, total healthcare investments increased to $47 billion, more than doubling the amount invested during the same period in 2020.Still, in order for life sciences, medical devices, and health products to be successful, founders and executives must not only find inventive ways to fund their companies, but also ensure that they are addressing real problems with verifiable research.